Compare Cassava Sciences Inc (FLNA) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Wipro Limited — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Wipro Limited trades at $1.82 (market cap $18.31B). The key difference: Wipro Limited is far larger — about 344.6× Cassava Sciences Inc's market cap, and Wipro Limited pays a 10.42% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | WIT | |
|---|---|---|
Market Cap | $53.14M | $18.31B |
Sector | Health | Technology |
52-Week High | $4.64 | $3.06 |
52-Week Low | $1.09 | $1.82 |
Enterprise Value | -$33.43M | $14.69B |
Dividend Yield | — | 10.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
WIT trades at $1.84, down 3.16% today, with bearish technical signals and mixed analyst sentiment. The company reported three consecutive quarterly EPS misses but maintains solid profitability with 14.25% net margin and 15.4% ROE. Recent news highlights AI partnerships and revenue challenges, with the stock showing weak momentum amid cautious client spending in the IT services sector.
The outlook remains cautious with near-term revenue pressure offset by AI transformation initiatives. Investment opportunity lies in valuation multiples below sector averages, while risks include persistent earnings misses and competitive IT services market dynamics. Wall Street shows divided sentiment with 19% buy ratings versus 33% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
